Media Pack|Subscribe|E-Newsletter
|Admin
Biotechnology Media Insights Logo
DermatologyEli Lilly

Eli Lilly Receives European Approval for Ebglyss in Moderate-to-Severe Atopic Dermatitis

BMI

Biotechnology Media Insights

Editorial Team · May 8, 2025

Eli Lilly announces European Commission approval of Ebglyss (lebrikizumab) for adults and adolescents with moderate-to-severe atopic dermatitis.

Dermatology skin treatment research with pharmaceutical laboratory equipment

Eli Lilly today announced that the European Commission has approved Ebglyss (lebrikizumab) for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older who are candidates for systemic therapy.

BMI

Biotechnology Media Insights

Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.

← Previous

Roche Receives FDA Approval for Columvi in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Next →

Gilead Sciences Presents Real-World Data for Sunlenca in Heavily Treatment-Experienced HIV Patients

Biotechnology Media Insights — Pharma & Life Sciences News